Therapeutic area
Rare syndromes frequently present severe, treatment-resistant symptoms and profound unmet need.
Rare genetic syndromes often involve neurological features, including difficult-to-control seizures.
Small patient populations and limited approved options make rigorous research and standardized therapeutics especially important.
Our pediatric clinical experience is directly relevant to rare syndromes that present with treatment-resistant seizures.
Better Cann Pharmaceutical was among the early Israeli companies involved in multi-center clinical research involving children and adolescents with severe, treatment-resistant epilepsy.
View Research